Pfizer indicated that Nivestym will be priced at a wholesale acquisition cost (WAC) of $350.40 per 480-mcg prefilled syringe, a WAC that is 30.3% lower than that of the reference Neupogen.
A representative from Pfizer told The Center for Biosimilars® in an email that Nivestym, an FDA-approved biosimilar filgrastim (referencing Neupogen), became commercially available in the United States on October 1. Pfizer began shipping the biosimilar to wholesalers on September 24.
Pfizer indicated that Nivestym will be priced at a wholesale acquisition cost (WAC) of $350.40 per 480-mcg prefilled syringe, a WAC that is 30.3% lower than that of the reference Neupogen, 20.3% lower than that of Zarxio (Sandoz’s biosimilar filgrastim), and 14.1% lower than that of Granix (or tbo-filgrastim, Teva’s follow-on filgrastim product cleared by the FDA prior to the establishment of a biosimilar approval pathway).
Nivestym, like its reference, is a granulocyte-colony stimulating factor that is approved to treat neutropenia in patients who are undergoing myelosuppressive chemotherapy or who have other types of severe neutropenia, and to mobilize autologous hematopoietic progenitor cells into peripheral blood for leukapheresis.
While the United States has 12 approved biosimilar products, Nivestym is only the fifth such product to launch; some biosimilar products, such as Sandoz’s etanercept, Erelzi, or Amgen’s adalimumab, Amjevita, have yet to launch despite having been approved in 2016, due in part to a complex patent landscape and ongoing legal challenges.
However, if recent trends are an indication of the future of the marketplace, patients may be able to access biosimilars—and health systems may be able to reap cost savings—sooner. It took Pfizer mere months to launch Nivestym, which was approved in July 2018. Similarly, Mylan and Biocon’s pegfilgrastim biosimilar, Fulphila, was approved in June 2018 and launched just 1 month later in July.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo
March 6th 2024Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.